The intervention being tested involves the use of Baxdrostat and Dapagliflozin, both administered as tablets. Baxdrostat is being evaluated for its potential to enhance the cardiovascular benefits of ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

Dapagliflozin Benefits Low-EF Heart Failure Regardless of Diuretic Dose: DAPA-HF Steve Stiles June 10, 2020 0 ...

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².

Gains from adding dapagliflozin to SOC treatment for HFrEF were seen in the additional life-years and QALYs gained, along with cost per QALY gained (incremental cost-effectiveness ratio [ICER]).

PHILADELPHIA, PA—Dapagliflozin added to optimal medical therapy results in meaningful improvements in symptoms and health-related quality of life in heart failure patients with reduced ejection ...

June 29, 2011 (San Diego, California) — Dapagliflozin in combination with metformin was found to increase blood glucose lowering compared with either agent alone in patients with newly diagnosed ...

The researchers found that 53% of the 78 participants in the dapagliflozin group and 30% of the 76 participants in the placebo group had MASH improvement without worsening of fibrosis (risk ratio ...